about
Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinaseImatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine modelsHistone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?Origin licensing and programmed cell death: a hypothesis.Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patientsCathepsin-Mediated Alterations in TGFß-Related Signaling Underlie Disrupted Cartilage and Bone Maturation Associated With Impaired Lysosomal Targeting.Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.Therapeutic approach of primary bone tumours by bisphosphonates.The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor.Involvement of sphingosine kinase/sphingosine 1-phosphate metabolic pathway in spondyloarthritis.IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.Oncostatin M is a growth factor for Ewing sarcoma.Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53.Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B.Response to: 'Does IL-38 act on macrophages and/or dendritic cells in arthritis?' by Jiang et al.Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK.Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II.Oncostatin M induces IL-33 expression in liver endothelial cells in mice and expands ST2+CD4+ lymphocytes.Epitope-function relationships of human leukemia inhibitory factor receptors using a novel set of anti-gp190 mAB.Leukemia inhibitory factor (LIF) and oncastsin M (OSM) high affinity binding require additional receptor subunits besides GP130 and GP190.Upmodulation of alpha v beta 1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: correlation with increased cell adhesion on fibronectin.Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance membrane expression of intercellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form.The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms.IL-1β and TNFα promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts.DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor.Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling.Calcific tendonitis of the rotator cuff: From formation to resorption.The enigmatic role of IL-38 in inflammatory diseases.Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor, increase or decrease its affinity for LIF.IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation.Direct anti-cancer effect of oncostatin M on chondrosarcoma.Wnt5a is expressed in spondyloarthritis and exerts opposite effects on enthesis and bone in murine organ and cell culturesOncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury
P50
Q28138574-ECEAC2FC-9304-4FAF-8649-8DFBC1FFBB33Q28540520-628FFA04-B1A1-40D9-95BC-F23A85BED298Q34393807-70F31057-4009-4700-9728-D9F372606E67Q34786469-D9C58865-638A-4A17-8D85-621AF050B4C2Q36146539-4EAA7C28-3F31-4AA5-A4A7-BF56AA7EAE71Q36730987-133F0C98-B873-4485-834F-49F63639CFF3Q36731426-64BDDC64-A2D5-4A3E-9614-D6C62D257D3AQ37781075-E94EDE36-8FE5-4596-ACAD-E4D5BDA85BF7Q38334664-FD8A1F45-AC77-43E9-A0FC-F07978183940Q38661790-2C7DA1DC-61B8-435A-8FBC-2EDDDCF0E65CQ38712399-0551CF5A-CB3A-4D02-B4B9-BF424861FAD6Q38809309-E0670622-BDDF-470F-867B-C3C8052FE760Q38981617-12924C87-FA3B-4B02-BC1F-30488F7C418DQ39108175-8942E55E-8B33-4643-95BE-36F8927BB119Q39277930-12F6A881-5117-4D18-9E33-DCCC661EE5CAQ39640530-1611AACE-41CB-4CB2-885F-D5BF88E8CEB8Q40138858-9C509031-5145-4EEC-8827-D56650467CB9Q40166492-3016116E-53FF-4655-BAEA-E602AEF7217AQ40175280-D605E539-9C7E-4BF3-8D88-3EA7754360FEQ40596056-423DC1F3-4A16-442F-9693-25ACCAE3D368Q40637150-E790431B-BAA5-4622-B787-4F5F06AEBC0BQ40649385-06855EB4-888D-4A27-8E8B-EB97EE92AB4FQ41065193-7A4F2E3D-DBF7-42C4-A69A-06939666E06EQ41220699-22ED7BFF-08D2-4B22-A0C0-486F1867D3BBQ41331294-1C290ED4-FF8A-49E0-8B4D-E32FF420CAFFQ41374791-EA873901-A277-45F8-8CCB-B857DAF4F2B3Q42084526-9F0D379B-8283-4E61-A2B7-60FE021E2114Q42824637-78503F7F-E364-4916-9B88-BB42D288AFB1Q43050400-4AC3A7FD-F6FB-44F3-8C62-61171D3A09F7Q44675042-A9750929-DF30-4097-A092-01C5556324B1Q45300522-3C5D10B2-2DD8-45B8-926E-2A36E18327B9Q46291802-B80794F7-9957-4046-B8E0-D78F4E1489A5Q47341313-915DE796-C2E0-4ACF-B400-2860E5DCB13CQ47714140-046B4BCD-2083-49DB-BC2B-F1B938EC4A4EQ50335902-3F57D44F-6031-4A46-BE06-58DD2743490CQ52661648-625918EE-B9F0-480E-9750-98AD821D6F3DQ53113146-426337C8-414F-4756-A030-0A56E94F71F6Q53265964-86A228A3-64EF-4648-B168-B3C083FCDEEAQ60263332-B838C126-3372-4FFC-A13B-0579BD0F5099Q61978406-0CBA0825-F412-405F-A8A2-FB24F8FAAB12
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Frédéric Blanchard
@ast
Frédéric Blanchard
@en
Frédéric Blanchard
@es
Frédéric Blanchard
@nl
Frédéric Blanchard
@sl
type
label
Frédéric Blanchard
@ast
Frédéric Blanchard
@en
Frédéric Blanchard
@es
Frédéric Blanchard
@nl
Frédéric Blanchard
@sl
prefLabel
Frédéric Blanchard
@ast
Frédéric Blanchard
@en
Frédéric Blanchard
@es
Frédéric Blanchard
@nl
Frédéric Blanchard
@sl
P106
P21
P31
P496
0000-0003-1055-2573